|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Creighton University |
|---|---|
| Information provided by: | Creighton University |
| ClinicalTrials.gov Identifier: | NCT00573547 |
Purpose
The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression |
Drug: Fluoxetine |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
| Official Title: | A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease |
| Estimated Enrollment: | 25 |
| Study Start Date: | February 2007 |
| Estimated Study Completion Date: | August 2008 |
Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.
Eligibility| Ages Eligible for Study: | 19 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Nebraska | |
| Creighton University Department of Psychiatry | |
| Omaha, Nebraska, United States, 68131 | |
| Creighton Department of Psychiatry | |
| Omaha, Nebraska, United States, 68131 | |
| Principal Investigator: | Syed P Sattar, MD | Creighton University Department of Psychiatry |
More Information
| Responsible Party: | Creighton University ( Syed Pirzada Sattar, M.D. ) |
| Study ID Numbers: | 05-13860 |
| Study First Received: | December 12, 2007 |
| Last Updated: | December 12, 2007 |
| ClinicalTrials.gov Identifier: | NCT00573547 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
depression chronic renal failures end stage renal disease |
|
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Renal Insufficiency Depression Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Kidney Failure, Chronic Depressive Disorder Serotonin Uptake Inhibitors Pharmacologic Actions Behavioral Symptoms |
Fluoxetine Serotonin Agents Urologic Diseases Mental Disorders Renal Insufficiency, Chronic Therapeutic Uses Mood Disorders Kidney Diseases Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents Kidney Failure |